ProKidney Corp. (PROK)
PROK Stock Price Chart
Explore ProKidney Corp. interactive price chart. Choose custom timeframes to analyze PROK price movements and trends.
PROK Company Profile
Discover essential business fundamentals and corporate details for ProKidney Corp. (PROK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
30 Jun 2021
Employees
204.00
Website
https://www.prokidney.comCEO
Bruce Culleton
Description
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
PROK Financial Timeline
Browse a chronological timeline of ProKidney Corp. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.13, while revenue estimate is $186.25k.
Earnings released on 15 May 2026
EPS came in at -$0.14 falling short of the estimated -$0.13 by -7.69%, while revenue for the quarter reached $226.00k , beating expectations by +125.44%.
Earnings released on 18 Mar 2026
EPS came in at -$0.14 surpassing the estimated -$0.16 by +12.50%, while revenue for the quarter reached $223.00k , beating expectations by +37.07k%.
Earnings released on 10 Nov 2025
EPS came in at -$0.12 matching the estimated -$0.12, while revenue for the quarter reached $217.00k .
Earnings released on 12 Aug 2025
EPS came in at -$0.13 surpassing the estimated -$0.14 by +7.14%, while revenue for the quarter reached $221.00k , beating expectations by +399.44%.
Earnings released on 12 May 2025
EPS came in at -$0.13 surpassing the estimated -$0.16 by +18.75%, while revenue for the quarter reached $230.00k .
Earnings released on 17 Mar 2025
EPS came in at -$0.17 falling short of the estimated -$0.14 by -21.43%, while revenue for the quarter reached $76.00k .
Earnings released on 12 Nov 2024
EPS came in at -$0.14 matching the estimated -$0.14.
Earnings released on 9 Aug 2024
EPS came in at -$0.16 surpassing the estimated -$0.17 by +5.88%.
Earnings released on 10 May 2024
EPS came in at -$0.16 surpassing the estimated -$0.25 by +36.00%.
Earnings released on 21 Mar 2024
EPS came in at -$0.09 surpassing the estimated -$0.19 by +52.63%, while revenue for the quarter reached $4.49m .
Earnings released on 14 Nov 2023
EPS came in at -$0.18 surpassing the estimated -$0.19 by +5.26%.
Earnings released on 10 Aug 2023
EPS came in at -$0.14 surpassing the estimated -$0.41 by +65.85%.
Earnings released on 11 May 2023
EPS came in at -$0.16 surpassing the estimated -$0.39 by +58.97%.
Earnings released on 28 Mar 2023
EPS came in at -$0.11 surpassing the estimated -$0.24 by +54.17%.
Earnings released on 14 Nov 2022
EPS came in at -$0.13 falling short of the estimated -$0.05 by -160.00%.
Earnings released on 12 Aug 2022
EPS came in at -$0.36 .
Earnings released on 16 May 2022
EPS came in at -$2.12 .
Earnings released on 24 Mar 2022
EPS came in at -$0.43 .
Earnings released on 15 Nov 2021
EPS came in at -$0.54 .
Earnings released on 16 Aug 2021
EPS came in at -$0.40 .
PROK Stock Performance
Access detailed PROK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
